{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:37:58Z","timestamp":1793644678441,"version":"4.5.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007928","name":"Ningbo Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ajp.2021.102664","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T02:04:31Z","timestamp":1620007471000},"page":"102664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"60","author":[{"given":"Yang","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-726X","authenticated-orcid":false,"given":"Biao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-2715","authenticated-orcid":false,"given":"Yunfeng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2021.102664_bib0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1517\/17425255.2015.1021331","article-title":"Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders","volume":"11","author":"Altamura","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ajp.2021.102664_bib0010","series-title":"Practice Guideline for the Treatment of Patients With Panic Disorder","author":"American Psychiatric Association","year":"2009"},{"key":"10.1016\/j.ajp.2021.102664_bib0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.0.CO;2-3","article-title":"Panic disorder. A long-term treatment study: fluoxetine vs imipramine","volume":"14","author":"Amore","year":"1999","journal-title":"Hum. Psychopharmacol.-Clin. Exp."},{"key":"10.1016\/j.ajp.2021.102664_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B","article-title":"Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram","volume":"14","author":"Amore","year":"1999","journal-title":"Hum. Psychopharmacol. Clin. Neurol."},{"key":"10.1016\/j.ajp.2021.102664_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/13651500600933984","article-title":"The new guidelines from the British Association for Psychopharmacology for anxiety disorders","volume":"10","author":"Anderson","year":"2006","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.ajp.2021.102664_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1440-1665.2003.00529.x","article-title":"Summary of guideline for the treatment of panic disorder and agoraphobia","volume":"11","author":"Andrews","year":"2003","journal-title":"Australasian Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1440-1665.2003.00529.x","article-title":"Summary of guideline for the treatment of panic disorder and agoraphobia","volume":"11","author":"Andrews","year":"2015","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/YIC.0b013e32835a5d2e","article-title":"Newer antidepressants and panic disorder: a meta-analysis","volume":"28","author":"Andrisano","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0045","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.brat.2007.01.005","article-title":"Implications of naturalistic use of pharmacotherapy in CBT treatment for panic disorder","volume":"45","author":"Arch","year":"2007","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.ajp.2021.102664_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ajp.2021.102664_bib0055","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4088\/JCP.v60n1205","article-title":"Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder","volume":"60","author":"Bakker","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0060","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"19","author":"Baldwin","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.ajp.2021.102664_bib0070","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ajp.2021.102664_bib0075","series-title":"Panic Disorder","author":"Bandelow","year":"2015"},{"key":"10.1016\/j.ajp.2021.102664_bib0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4088\/JCP.v65n0317","article-title":"Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison","volume":"65","author":"Bandelow","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0085","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","article-title":"What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?","volume":"67","author":"Bandelow","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-2004-832593","article-title":"Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study","volume":"37","author":"Bertani","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011567.pub2","article-title":"Antidepressants and benzodiazepines for panic disorder in adults","author":"Bighelli","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajp.2021.102664_bib0100","series-title":"Antidepressants and Benzodiazepines for Panic Disorder in Adults","author":"Bighelli","year":"2016"},{"key":"10.1016\/j.ajp.2021.102664_bib0105","article-title":"Network meta-analysis using R: a review of currently available automated packages","volume":"9","author":"Binod","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajp.2021.102664_bib0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1521\/pedi.1996.10.2.185","article-title":"The effect of fluvoxamine, cognitive therapy, and placebo on abnormal personality traits in 44 patients with panic disorder","volume":"10","author":"Black","year":"1996","journal-title":"J. Pers. Disord."},{"key":"10.1016\/j.ajp.2021.102664_bib0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13651509709069206","article-title":"The value of selective serotonin re-uptake inhibitors (SSRIs) in the treatment of panic disorder with and without agoraphobia","volume":"1","author":"Boerner","year":"1997","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.ajp.2021.102664_bib0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1192\/bjp.187.4.352","article-title":"Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study","volume":"187","author":"Bradwejn","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0125","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.160.8.1432","article-title":"Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?","volume":"160","author":"Bruce","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17305\/bjbms.2003.3524","article-title":"Clomipramine and fluoxetine effects in the treatment of panic disorder","volume":"3","author":"Cavaljuga","year":"2003","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.ajp.2021.102664_bib0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/da.20654","article-title":"Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-V","volume":"27","author":"Craske","year":"2010","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.ajp.2021.102664_bib0140","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.psym.2013.02.010","article-title":"Panic disorder prevalence among patients referred for an electrocardiogram in a nigerian teaching hospital","volume":"54","author":"Esan","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ajp.2021.102664_bib0145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4088\/JCP.v68n0108","article-title":"Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release","volume":"68","author":"Ferguson","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0150","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/14656566.2011.562200","article-title":"New treatment options for panic disorder: clinical trials from 2000 to 2010","volume":"12","author":"Freire","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ajp.2021.102664_bib0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0019-5545.196975","article-title":"Clinical practice guidelines for the management of generalised anxiety disorder (GAD) and panic disorder (PD)","volume":"59","author":"Gautam","year":"2017","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0160","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2012.0407","article-title":"\u2019It\u2019s the way that you look at it\u2019--a cognitive neuropsychological account of SSRI action in depression","author":"Harmer","year":"2013","journal-title":"Philos. Trans. R. Soc. B: Biol. Sci."},{"key":"10.1016\/j.ajp.2021.102664_bib0165","first-page":"1067","article-title":"Benzodiazepines for panic disorder: not \"NICE\", but may still be beneficial","author":"Harrisonread","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ajp.2021.102664_bib0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.2009.01517.x","article-title":"A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder","volume":"122","author":"Hendriks","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ajp.2021.102664_bib0175","first-page":"S38","article-title":"Cochrane handbook for systematic reviews of interventions version 5.0.1. The cochrane collaboration","volume":"5","author":"Higgins","year":"2008","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle Pathologie und Pharmakologie"},{"key":"10.1016\/j.ajp.2021.102664_bib0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00004714-199310000-00004","article-title":"Effect of fluvoxamine on panic disorder","volume":"13","author":"Hoehn-Saric","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1099-1077(199903)14:2<119::AID-HUP77>3.0.CO;2-1","article-title":"Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR","volume":"14","author":"Holland","year":"1999","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.ajp.2021.102664_bib0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.yic.0000171518.25963.63","article-title":"A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan","volume":"20","author":"Kamijima","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0924-977X(01)00100-6","article-title":"Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors","volume":"11","author":"Kasper","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0200","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1440-1819.2005.01430.x","article-title":"Panic disorder with and without agoraphobia: comorbidity within a half-year of the onset of panic disorder","volume":"59","author":"Kikuchi","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ajp.2021.102664_bib0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/tcrm.2007.3.1.59","article-title":"Venlafaxine extended release (XR) in the treatment of panic disorder","volume":"3","author":"Kjernisted","year":"2007","journal-title":"Ther. Clin. Risk Manage."},{"key":"10.1016\/j.ajp.2021.102664_bib0210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/S1352465801001138","article-title":"A brief internet-based treatment for panic disorder","volume":"29","author":"Klein","year":"2001","journal-title":"Behav. Cogn. Psychother."},{"key":"10.1016\/j.ajp.2021.102664_bib0215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1017\/S0033291710000930","article-title":"A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder","volume":"41","author":"Koszycki","year":"2011","journal-title":"Psychol. Med."},{"issue":"13","key":"10.1016\/j.ajp.2021.102664_bib0220","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ajp.2021.102664_bib0225","article-title":"Reboxetine, why the discrepancy between NICE guidance? and where do we go?","author":"Krishnadas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ajp.2021.102664_bib0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0269881195009002011","article-title":"The SSRIs: advantages, disadvantages and differences","volume":"9","author":"Lane","year":"1995","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1600-0447.1997.tb00389.x","article-title":"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ajp.2021.102664_bib0240","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ajp.2021.102664_bib0245","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.v64n0606","article-title":"Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder","volume":"64","author":"Lepola","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0250","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4088\/JCP.08m04238","article-title":"A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder","volume":"70","author":"Liebowitz","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation","volume":"173","author":"Londborg","year":"1998","journal-title":"Br. J. Psychiatry J. Mental Sci."},{"key":"10.1016\/j.ajp.2021.102664_bib0260","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10401230309085686","article-title":"Imiprmaine vs. Sertraline in panic disorder: 24-week treatment completers","volume":"15","author":"Matig","year":"2003","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0265","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1037\/a0019552","article-title":"Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificity","volume":"78","author":"Meuret","year":"2010","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.ajp.2021.102664_bib0270","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1176\/ajp.155.11.1570","article-title":"Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo","volume":"155","author":"Michelson","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0275","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder - randomised, placebo-controlled trial","volume":"179","author":"Michelson","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0280","article-title":"Pharmacological therapy in panic disorder: current guidelines and novel drugs discovery for treatment-resistant patient","author":"Mohamed","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.ajp.2021.102664_bib0285","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4088\/JCP.v60n0907","article-title":"Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages","volume":"60","author":"Moroz","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0290","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"Nair","year":"1996","journal-title":"Anxiety"},{"key":"10.1016\/j.ajp.2021.102664_bib0295","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1590\/S0100-879X2011000400015","article-title":"Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine","volume":"44","author":"Nardi","year":"2011","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ajp.2021.102664_bib0300","first-page":"13","article-title":"Current pharmacological interventions in panic disorder","author":"Nardi","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ajp.2021.102664_bib0305","series-title":"Generalised Anxiety Disorder and Panic Disorder (with or Without Agoraphobia) in Adults: Management in Primary, Secondary and Community Care","author":"National Institute For Health And Care Excellence","year":"2011"},{"key":"10.1016\/j.ajp.2021.102664_bib0310","first-page":"349","article-title":"Diazepam versus alprazolam for the treatment of panic disorder","volume":"57","author":"Noyes","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0315","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.167.3.374","article-title":"Paroxetine in the treatment of panic disorder - a randomized, double-blind, placebo-controlled study","volume":"167","author":"Oehrberg","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0320","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2001-14283","article-title":"A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study","volume":"34","author":"Perna","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0325","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/ajp.155.9.1189","article-title":"Sertraline in the treatment of panic disorder: a double-blind multicenter trial","volume":"155","author":"Pohl","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0330","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial","volume":"55","author":"Pollack","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder","volume":"194","author":"Pollack","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ajp.2021.102664_bib0340","series-title":"Psychological Therapies for Panic Disorder With or Without Agoraphobia in Adults: A Network Meta-analysis","author":"Pompoli","year":"2016"},{"key":"10.1016\/j.ajp.2021.102664_bib0345","first-page":"349","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","author":"Puhan","year":"2014","journal-title":"BMJ-Br. Med. J."},{"key":"10.1016\/j.ajp.2021.102664_bib0350","first-page":"33","article-title":"Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: a meta analysis of common side effects in acute treatment","author":"Quagliato","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0355","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00004714-199710000-00008","article-title":"Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance","volume":"17","author":"Rosenbaum","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0360","first-page":"641","article-title":"Australian and New Zealand. Clinical practice guidelines for the treatment of panic disorder and agoraphobia. Australian & New Zealand","volume":"37","author":"Royal","year":"2003","journal-title":"J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/anxi.3070010402","article-title":"Course and outcome in panic disorder: a review of recent follow-up studies","volume":"1","author":"Roy-Byrne","year":"2015","journal-title":"Anxiety"},{"key":"10.1016\/j.ajp.2021.102664_bib0370","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(06)69418-X","article-title":"Panic disorder","volume":"368","author":"Roy-Byrne","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ajp.2021.102664_bib0375","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-2007-979311","article-title":"Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine","volume":"31","author":"Sandmann","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0380","first-page":"279","article-title":"Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study","volume":"18","author":"Seedat","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102664_bib0385","first-page":"E255","article-title":"Reboxetine in clinical practice: a review","volume":"163","author":"Sepede","year":"2012","journal-title":"Clin. Terapeutica"},{"key":"10.1016\/j.ajp.2021.102664_bib0390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0887-6185(96)00008-4","article-title":"Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia","volume":"10","author":"Sharp","year":"1996","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.ajp.2021.102664_bib0395","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.v66n0105","article-title":"Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder","volume":"66","author":"Sheehan","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0400","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0405","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/14737175.2014.963057","article-title":"The reappraisal of benzodiazepines in the treatment of anxiety and related disorders","volume":"14","author":"Starcevic","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ajp.2021.102664_bib0410","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/NDT.S965","article-title":"The therapeutic potential of escitalopram in the treatment of panic disorder","volume":"3","author":"Townsend","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ajp.2021.102664_bib0415","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1590\/S0004-282X2000000600008","article-title":"Double-blind clonazepam vs placebo in panic disorder treatment","volume":"58","author":"Valenca","year":"2000","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.ajp.2021.102664_bib0420","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/S1516-31802003000200009","article-title":"Therapeutic response to benzodiazepine in panic disorder subtypes","volume":"121","author":"Valenca","year":"2003","journal-title":"Sao Paulo Med. J."},{"key":"10.1016\/j.ajp.2021.102664_bib0425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.v63n0107","article-title":"Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder","volume":"63","author":"Versiani","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0430","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.170.6.549","article-title":"The effect of citalopram in panic disorder","volume":"170","author":"Wade","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102664_bib0435","first-page":"11","article-title":"Short-term efficacy and tolerability of paroxetine versus placebo for panic disorder: a meta-analysis of randomized controlled trials","author":"Zhang","year":"2020","journal-title":"Front. Pharmacol."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201821001209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201821001209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:37:56Z","timestamp":1761755876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201821001209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":87,"alternative-id":["S1876201821001209"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2021.102664","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2021.102664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102664"}}